Drug
Icotinib clinical trials
Also written BPI-2009.
Includes 6 studies of Icotinib hydrochloride.
- studies test it
- 74
- open now
- 8
- in phase 3
- 11
- first study started
- 2009
Keep track of what changes. Save the icotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
74 studies that test it; most in 2014 (15)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 15 |
| 2015 | 9 |
| 2016 | 10 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 8
- Phase 2
- 46
- Phase 3
- 11
- Phase 4
- 9
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 35 · Other 39
Betta Pharmaceuticals Co., Ltd. (35) · Sun Yat-sen University (5) · Tianjin Medical University Cancer Institute and Hospital (4) · Nanfang Hospital, Southern Medical University (3) · Zhejiang Cancer Hospital (2) · Chinese Academy of Medical Sciences (2) · Zhejiang University (2) · Yuhong Li (1)
Often tested with
Tested in the same studies.
Befotertinib (2) · Gemcitabine (2) · Bevacizumab (1) · Anlotinib (1) · Gefitinib (1) · Rezivertinib (1) · Ensartinib (1) · Benmelstobart (1)
Studies
Open first, then newest update. How each study uses icotinib is read from its arms, and is right about nine times in ten.
Testing it · 74
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingEarly Phase 1Fuzhou General HospitalNCT07458919Written as Icotinib/Gefitinib
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingPhase 3The First Affiliated Hospital of Guangzhou Medical UniversityNCT06955325Written as Icotinib
- Befotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsRecruitingPhase 2Sun Yat-sen UniversityNCT06517953Written as Icotinib
- A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete ResectionNot yet recruitingPhase 2Wu NanNCT05514314Written as Icotinib
- Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNot yet recruitingPhase 2Liaoning Cancer Hospital & InstituteNCT05132985Written as Icotinib
- A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT05104788Written as Icotinib
- Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.RecruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT03992885Written as Icotinib
- Adjuvant Chemotherapy With or Without Intercalated IcotinibNot yet recruitingNot applicableNanfang Hospital, Southern Medical UniversityNCT03983811Written as Icotinib
- Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05263947Written as Icotinib
- Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedPhase 2Sun Yat-sen UniversityNCT02264210Written as Icotinib
- Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR MutationTerminatedPhase 3Sun Yat-sen UniversityNCT01996098Written as 6-month Icotinib
- Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingPhase 2Betta Pharmaceuticals Co., Ltd.NCT05007938Written as Icotinib
- Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional ChemotherapyCompletedPhase 2Yuhong LiNCT01973725Written as Icotinib Hydrochloride
- Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR MutationCompletedPhase 2Betta Pharmaceuticals Co., Ltd.NCT02044328Written as Icotinib
- Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedPhase 2Li PengNCT02934256Written as Icotinib
- Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownPhase 3Betta Pharmaceuticals Co., Ltd.NCT02448797Written as Icotinib
- Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCCompletedPhase 2Tianjin Medical University Cancer Institute and HospitalNCT03736837Written as Anlotinib Plus Icotinib
- Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line TherapyTerminatedPhase 2Sun Yat-sen UniversityNCT02362230Written as Icotinib
- Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR MutationStatus unknownPhase 2Henan Cancer HospitalNCT02737774Written as Icotinib
- Cryotherapy Combine Icotinib for Advanced NSCLC TreatmentCompletedPhase 4Fuda Cancer Hospital, GuangzhouNCT02744664Written as Icotinib
See all 74 studies that test icotinib →
Given in every arm · 5 — icotinib is usual care beside what is tested
- Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLCStatus unknownPhase 3Tianjin Medical University Cancer Institute and HospitalNCT04797806Written as Icotinib
- Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary AdenocarcinomaCompletedPhase 3Shanghai University of Traditional Chinese MedicineNCT02889692Written as Icotinib®
- Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerStatus unknownNot applicableThe First Affiliated Hospital of Soochow UniversityNCT03766490Written as Icotinib
- Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR MutationStatus unknownPhase 2Betta Pharmaceuticals Co., Ltd.NCT03754530Written as Icotinib
- Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerStatus unknownPhase 4Qilu Hospital of Shandong UniversityNCT02031601Written as Icotinib
As the comparator · 2 — what is tested is compared with icotinib
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedPhase 2/3Betta Pharmaceuticals Co., Ltd.NCT04206072Written as Icotinib Hydrochloride Tablets
- Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaStatus unknownPhase 4Betta Pharmaceuticals Co., Ltd.NCT02103257Written as Icotinib
Codes
What other systems call icotinib · ClinicalTrials.gg INT005324
- MeSH (NLM) C531470icotinibOne source NLM
- UNII (FDA) 9G6U5L461QICOTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q16868421icotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C138996IcotinibOne source FDA
- DrugBank DB11737One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531470 | icotinib | One source NLM |
| UNII (FDA) | 9G6U5L461Q | ICOTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q16868421 | icotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C138996 | Icotinib | One source FDA |
| DrugBank | DB11737 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.